Rankings
▼
Calendar
AMRX FY 2025 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
FY 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$3.0B
+8.0% YoY
Gross Profit
$1.1B
37.6% margin
Operating Income
$423M
14.0% margin
Net Income
$72M
2.4% margin
EPS (Diluted)
$0.22
Cash Flow
Operating Cash Flow
$340M
Free Cash Flow
$270M
Stock-Based Comp.
$32M
Balance Sheet
Total Assets
$3.7B
Total Liabilities
$3.7B
Stockholders' Equity
-$71M
Cash & Equivalents
$311M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.0B
$2.8B
+8.0%
Gross Profit
$1.1B
$1.0B
+11.3%
Operating Income
$423M
$249M
+69.7%
Net Income
$72M
-$117M
+161.6%
← Q4 2024
All Quarters
Q1 2025 →